Published in J Clin Invest on October 18, 2010
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A (2011) 1.85
Scraping fibrosis: expressway to the core of fibrosis. Nat Med (2011) 1.82
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol (2011) 1.79
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol (2012) 1.49
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology (2012) 1.25
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med (2011) 1.10
Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem (2012) 1.07
Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol (2010) 1.06
Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol (2012) 1.05
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Touch of chemokines. Front Immunol (2012) 1.00
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One (2013) 0.96
Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol (2015) 0.94
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov (2016) 0.92
The chemokine CCL3 promotes experimental liver fibrosis in mice. PLoS One (2013) 0.87
Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond) (2012) 0.87
Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol (2014) 0.86
Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care (2013) 0.85
Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. Int J Clin Exp Pathol (2013) 0.84
Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury. PLoS One (2012) 0.82
Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II. PLoS One (2013) 0.81
Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB J (2014) 0.81
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One (2016) 0.81
Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci (2016) 0.81
Physical exercise reduces the expression of RANTES and its CCR5 receptor in the adipose tissue of obese humans. Mediators Inflamm (2014) 0.80
Chemokines and Glycosaminoglycans. Front Immunol (2015) 0.79
Are mast cells instrumental for fibrotic diseases? Front Pharmacol (2014) 0.79
An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. PLoS One (2014) 0.79
RANTES antagonism: a promising approach to treat chronic liver diseases. J Hepatol (2011) 0.78
Novel Pharmacotherapy Options for NASH. Dig Dis Sci (2016) 0.78
The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis. PLoS One (2017) 0.77
Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. Dig Dis Sci (2015) 0.77
Liver inflammation and fibrosis. J Clin Invest (2017) 0.77
Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. J Neuroinflammation (2014) 0.77
Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells. Hepatology (2017) 0.76
Ces3/TGH Deficiency Attenuates Steatohepatitis. Sci Rep (2016) 0.76
Anti-chemokine therapy for the treatment of hepatic fibrosis: an attractive approach. Hepatology (2011) 0.76
Chunggan extract, a traditional herbal formula, ameliorated alcohol-induced hepatic injury in rat model. World J Gastroenterol (2014) 0.76
Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One (2017) 0.75
Inflammation-associated upregulation of the sulfated steroid transporter Slc10a6 in mouse liver and macrophage cell lines. Hepatol Res (2015) 0.75
C-C Motif Chemokine 5 Attenuates Angiotensin II-Dependent Kidney Injury by Limiting Renal Macrophage Infiltration. Am J Pathol (2016) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
How to Face Chronic Liver Disease: The Sinusoidal Perspective. Front Med (Lausanne) (2017) 0.75
Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol (2017) 0.75
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One (2012) 0.75
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight (2017) 0.75
Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One (2017) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet (2003) 26.59
Liver fibrosis. J Clin Invest (2005) 17.27
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest (2005) 8.58
T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 6.23
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
RANTES: a versatile and controversial chemokine. Trends Immunol (2001) 2.87
Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation (2002) 2.69
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem (1996) 2.56
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 2.23
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol (2003) 2.07
Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol (1998) 2.01
Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A (2002) 1.61
Impaired T cell function in RANTES-deficient mice. Clin Immunol (2002) 1.60
Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest (1993) 1.54
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Isolation and culture of hepatic stellate cells. Methods Mol Med (2005) 1.45
Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology (2008) 1.39
Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol (2008) 1.36
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J (1999) 1.28
Immune interactions in hepatic fibrosis. Clin Liver Dis (2008) 1.23
Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis (2006) 1.18
CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver. Eur J Immunol (2004) 1.16
CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol (2007) 1.15
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis (2008) 1.08
Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int (2006) 1.07
A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05
Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol (2003) 0.99
Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology (2004) 0.98
Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm (2004) 0.95
From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. Hepatology (2004) 0.86
Retinol uptake and metabolism, and cellular retinol binding protein expression in an in vitro model of hepatic stellate cells. Mol Cell Biochem (1998) 0.85
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
The genome of the protist parasite Entamoeba histolytica. Nature (2005) 5.33
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 4.73
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (2010) 4.72
Roles of TGF-beta in hepatic fibrosis. Front Biosci (2002) 4.15
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med (2002) 4.02
Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2008) 3.81
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 3.69
Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity (2007) 3.61
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol (2002) 3.17
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res (2010) 3.03
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2007) 2.85
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol (2010) 2.71
Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation (2002) 2.69
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation (2010) 2.69
Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res (2004) 2.68
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation (2007) 2.54
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 2.45
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol (2008) 2.42
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab (2010) 2.33
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation (2004) 2.30
Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol (2009) 2.27
Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol (2003) 2.24
Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res (2007) 2.22
Heat stress response in plants: a complex game with chaperones and more than twenty heat stress transcription factors. J Biosci (2004) 2.22
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health (2008) 2.20
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell (2013) 2.19
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation (2013) 2.18
Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med (2004) 2.17
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res (2005) 2.15
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13
Neutrophil secretion products pave the way for inflammatory monocytes. Blood (2008) 2.12
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta (2007) 2.10
Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science (2008) 2.10
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09
Statin treatment after onset of sepsis in a murine model improves survival. Circulation (2005) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology (2011) 2.05
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol (2002) 1.99
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98
Involvement of TRAIL and its receptors in viral hepatitis. FASEB J (2002) 1.97
Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol (2011) 1.95
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92
Macrophage migration inhibitory factor in cardiovascular disease. Circulation (2008) 1.91
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (2002) 1.85